Hunt S A, Stinson E B
Annu Rev Med. 1981;32:213-20. doi: 10.1146/annurev.me.32.020181.001241.
Based on the Stanford series of 188 patients, we emphasize that orthotopic cardiac transplantation represents a reasonable therapeutic option for the patient with inoperable end-stage heart disease. Current expectations for survival equal those for organ survival in cadaver renal transplant series and offer a rehabilitation potential of over 90%. Most of the complications limiting survival are due to the currently available means of immunosuppression and, therefore, advances in the field of immunosuppression can be expected to have a major positive influence on survival rates.
基于斯坦福大学的188例患者系列研究，我们强调原位心脏移植对于患有无法手术的终末期心脏病患者而言是一种合理的治疗选择。目前的生存预期与尸体肾移植系列研究中的器官存活预期相当，且康复潜力超过90%。大多数限制生存的并发症是由于目前可用的免疫抑制手段，因此，免疫抑制领域的进展有望对生存率产生重大的积极影响。
